Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach

被引:1
|
作者
Wang, Xiaofei [1 ]
George, Stephen L. [1 ]
机构
[1] Duke Univ, Sch Med, Dept Biostat & Bioinformat, 2424 Erwin Rd,Suite 1102, Durham, NC 27705 USA
关键词
Average hazard ratio; clinical trial design; delayed treatment effect; futility rules; non-proportional hazards; SAMPLE-SIZE; SURVIVAL; DESIGN; TESTS;
D O I
10.1177/17407745231181908
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Standard futility analyses designed for a proportional hazards setting may have serious drawbacks when non-proportional hazards are present. One important type of non-proportional hazards occurs when the treatment effect is delayed. That is, there is little or no early treatment effect but a substantial later effect. Methods We define optimality criteria for futility analyses in this setting and propose simple search procedures for deriving such rules in practice. Results We demonstrate the advantages of the optimal rules over commonly used rules in reducing the average number of events, the average sample size, or the average study duration under the null hypothesis with minimal power loss under the alternative hypothesis. Conclusion Optimal futility rules can be derived for a non-proportional hazards setting that control the loss of power under the alternative hypothesis while maximizing the gain in early stopping under the null hypothesis.
引用
收藏
页码:603 / 612
页数:10
相关论文
共 15 条
  • [1] Methods for non-proportional hazards in clinical trials: A systematic review
    Bardo, Maximilian
    Huber, Cynthia
    Benda, Norbert
    Brugger, Jonas
    Fellinger, Tobias
    Galaune, Vaidotas
    Heinz, Judith
    Heinzl, Harald
    Hooker, Andrew C.
    Klinglmueller, Florian
    Koenig, Franz
    Mathes, Tim
    Mittlboeck, Martina
    Posch, Martin
    Ristl, Robin
    Friede, Tim
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2024, 33 (06) : 1069 - 1092
  • [2] Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated
    Royston, Patrick
    Parmar, Mahesh K. B.
    BMC MEDICAL RESEARCH METHODOLOGY, 2016, 16
  • [3] Quantifying treatment differences in confirmatory trials under non-proportional hazards
    Jimenez, Jose L.
    JOURNAL OF APPLIED STATISTICS, 2022, 49 (02) : 466 - 484
  • [4] A MCP-Mod approach to designing and analyzing survival trials with potential non-proportional hazards
    Luo, Xiaodong
    Sun, Yuan
    Xu, Zhixing
    PHARMACEUTICAL STATISTICS, 2022, 21 (06) : 1294 - 1308
  • [5] A Comparison of Statistical Methods for Time-To-Event Analyses in Randomized Controlled Trials Under Non-Proportional Hazards
    Klinglmueller, Florian
    Fellinger, Tobias
    Koenig, Franz
    Friede, Tim
    Hooker, Andrew C.
    Heinzl, Harald
    Mittlboeck, Martina
    Brugger, Jonas
    Bardo, Maximilian
    Huber, Cynthia
    Benda, Norbert
    Posch, Martin
    Ristl, Robin
    STATISTICS IN MEDICINE, 2025, 44 (05)
  • [6] Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated
    Patrick Royston
    Mahesh K.B. Parmar
    BMC Medical Research Methodology, 16
  • [7] Critical review of oncology clinical trial design under non-proportional hazards
    Ananthakrishnan, Revathi
    Green, Stephanie
    Previtali, Alessandro
    Liu, Rong
    Li, Daniel
    LaValley, Michael
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 162
  • [8] An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
    Royston, Patrick
    Parmar, Mahesh K. B.
    TRIALS, 2014, 15
  • [9] Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
    Castanon, Eduardo
    Sanchez-Arraez, Alvaro
    Alvarez-Mancenido, Felipe
    Jimenez-Fonseca, Paula
    Carmona-Bayonas, Alberto
    EUROPEAN JOURNAL OF CANCER, 2020, 136 : 159 - 168
  • [10] An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
    Patrick Royston
    Mahesh KB Parmar
    Trials, 15